NASDAQ:CASI CASI Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.51 -0.01 (-0.66 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$1.47Now: $1.51▼$1.5350-Day Range$1.52MA: $1.75▼$1.9452-Week Range$1.15Now: $1.51▼$3.67Volume420,080 shsAverage Volume322,514 shsMarket Capitalization$187.16 millionP/E RatioN/ADividend YieldN/ABeta0.74 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, CASI Pharmaceuticals has a forecasted upside of 131.8% from its current price of $1.51.Amount of Analyst CoverageCASI Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCASI Pharmaceuticals has received 178 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCASI Pharmaceuticals has received 181 “underperform” votes. (Add your “underperform” vote.)Community SentimentCASI Pharmaceuticals has received 50.42% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote “Outperform” if you believe CASI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,647,900.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 24.75% of the stock of CASI Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 18.46% of the stock of CASI Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($0.25) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CASI Previous Symbol CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone240-864-2600Debt Debt-to-Equity RatioN/A Current Ratio13.35 Quick Ratio13.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.13 million Price / Sales45.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book1.99Profitability EPS (Most Recent Fiscal Year)($0.42) Net Income$-46,030,000.00 Net Margins-388.71% Return on Equity-53.15% Return on Assets-37.88%Miscellaneous Employees124 Outstanding Shares123,944,000Market Cap$187.16 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $1.51 -0.01 (-0.66 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CASI News and Ratings via Email Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions How has CASI Pharmaceuticals' stock price been impacted by Coronavirus? CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CASI shares have decreased by 7.4% and is now trading at $1.51. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of CASI Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CASI Pharmaceuticals. When is CASI Pharmaceuticals' next earnings date? CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for CASI Pharmaceuticals. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc (NASDAQ:CASI) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $2.67 million for the quarter, compared to the consensus estimate of $3.75 million. CASI Pharmaceuticals had a negative return on equity of 53.15% and a negative net margin of 388.71%. View CASI Pharmaceuticals' earnings history. What price target have analysts set for CASI? 1 Wall Street analysts have issued 12-month price objectives for CASI Pharmaceuticals' stock. Their forecasts range from $3.50 to $3.50. On average, they expect CASI Pharmaceuticals' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 131.8% from the stock's current price. View analysts' price targets for CASI Pharmaceuticals. Are investors shorting CASI Pharmaceuticals? CASI Pharmaceuticals saw a decrease in short interest in August. As of August 14th, there was short interest totaling 1,430,000 shares, a decrease of 21.4% from the July 30th total of 1,820,000 shares. Based on an average trading volume of 431,400 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.3% of the shares of the company are sold short. View CASI Pharmaceuticals' Short Interest. Who are some of CASI Pharmaceuticals' key competitors? Some companies that are related to CASI Pharmaceuticals include Nantkwest (NK), Cellectis (CLLS), Agenus (AGEN), Checkmate Pharmaceuticals (INBX), Osiris Therapeutics (OSIR), BioCryst Pharmaceuticals (BCRX), Tcr2 Therapeutics (TCRR), Passage Bio (PASG), Poseida Therapeutics (PSTX), Allovir (ALVR), Autolus Therapeutics (AUTL), Aerie Pharmaceuticals (AERI), Scholar Rock (SRRK), Fusion Pharmaceuticals (FUSN) and Aptose Biosciences (APTO). View all competitors. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), Opko Health (OPK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Overstock.com (OSTK), Caladrius Biosciences (CLBS), Pure Storage (PSTG), QUALCOMM (QCOM) and Catalyst Pharmaceuticals (CPRX). Who are CASI Pharmaceuticals' key executives? CASI Pharmaceuticals' management team includes the following people: Dr. Wei-Wu He, Chairman & CEO (Age 54)Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53) What is CASI Pharmaceuticals' stock symbol? CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI." Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Shields & Co. LLC (1.31%), Wellington Shields Capital Management LLC (1.09%), Charles Schwab Investment Management Inc. (0.27%), Bridgeway Capital Management Inc. (0.17%), Nuveen Asset Management LLC (0.15%) and Bank of New York Mellon Corp (0.14%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, Larry Zhang and Wei-Wu He. View institutional ownership trends for CASI Pharmaceuticals. Which major investors are selling CASI Pharmaceuticals stock? CASI stock was sold by a variety of institutional investors in the last quarter, including Vident Investment Advisory LLC, Goldman Sachs Group Inc., UBS Group AG, and Nuveen Asset Management LLC. View insider buying and selling activity for CASI Pharmaceuticals. Which major investors are buying CASI Pharmaceuticals stock? CASI stock was acquired by a variety of institutional investors in the last quarter, including Wellington Shields & Co. LLC, Bridgeway Capital Management Inc., Charles Schwab Investment Management Inc., WINTON GROUP Ltd, Jane Street Group LLC, Bank of America Corp DE, Heritage Investors Management Corp, and Bank of New York Mellon Corp. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, Larry Zhang, and Wei-Wu He. View insider buying and selling activity for CASI Pharmaceuticals. How do I buy shares of CASI Pharmaceuticals? Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CASI Pharmaceuticals' stock price today? One share of CASI stock can currently be purchased for approximately $1.51. How big of a company is CASI Pharmaceuticals? CASI Pharmaceuticals has a market capitalization of $187.16 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe. What is CASI Pharmaceuticals' official website? The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com. How can I contact CASI Pharmaceuticals? CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
